Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07620444
Starting soon Observational

Spectral Precise Image-Colon Cancer

NCT07620444 · tracked via the Priya Life Science China tracker
Sponsor
Philips Clinical & Medical Affairs Global
Phase
Observational
Started
2026-06-01
Last updated
2026-06-02

Condition(s) studied

Colon Cancer Patients

Investigational drug(s) / intervention(s)

This is an observational study

This is an observational study: This is an observational study

Study summary

This is a single-center, comparative, observational study. Datasets will be collected from patients with pathologically confirmed colon cancer who undergo abdomen-pelvis enhanced spectral CT scan.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Patients pathologically confirmed with colon cancer via endoscopic biopsy. 2. Patients who underwent preoperative abdominopelvic enhanced spectral CT. 3. Study participant with age ≥ 18 years old. 4. Study participants that have signed Informed Consent Form (ICF). Exclusion Criteria: 1. The clinical data or pathological information is considered incomplete after evaluation by the investigator. 2. The investigator determined that poor image quality (e.g. obvious artifacts, missing critical scan layers) would not satisfy post-processing analysis. 3. Data of patients deemed inappropriate for inclusion after evaluation by the investigator.

Primary outcome measure(s)

  • subjective overall Image quality using 5-point Likert scale(1-5) — From the date of image reconstruction completion to the date of image evaluation completion, anticipated 3 Months.
    Radiologist will evaluate the overall image quality using 5 Likert scale ranging from 1(poor) to 5 (Excellent)
  • Objective image quality — From the date reconstruction completion to the date of image evaluation completion, anticipated 3months.
    The objective image quality is evaluated by measuring the CT value shown in the image.

Trial sites (1)

FacilityCityRegionStatus
Sun Yat-sen cancer center Guangzhou Guangdong

More Philips Clinical & Medical Affairs Global trials in China

Spectral Precise Image Study for Brain Tumors Recruiting
Clinical Study of Spectral CT Starting soon
Clinical Study of Spectral CT Verida Starting soon
Spectral Precise Image Study for Coronary Artery Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07620444 on ClinicalTrials.gov ↗ ← All trials in China